← back to search

Horst Zitzelsberger

Helmholtz Zentrum München · DE
Area of research
Cancer Research · Otorhinolaryngology
Research interest
Research interests include Head and Neck Cancer Studies, Cancer Genomics and Diagnostics, MicroRNA in disease regulation, and Cancer-related molecular mechanisms research.
h-index
48
citations
6,997
works
339
NIH funding
primary concept
email

Recent publications

EGFR-mediated local invasiveness and response to Cetuximab in head and neck cancer
Molecular Cancer 2025cited by 16position: middledoi
The <scp>TBLR1</scp> / <scp>TBL1</scp> Co‐Factor Complex Acts as a Transcriptional Checkpoint in the Brown Adipose Tissue Response to Prolonged Cold Exposure
The FASEB Journal 2025cited by 1position: middledoi
Adjuvant (chemo)radiotherapy for patients with head and neck cancer: can comorbidity risk scores predict outcome?
Strahlentherapie und Onkologie 2024cited by 3position: middledoi
Metabolic pathway-based subtypes associate glycan biosynthesis and treatment response in head and neck cancer
npj Precision Oncology 2024cited by 1position: middledoi
Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling
Journal of Hepatology 2023cited by 91position: middledoi
A Novel Subgroup of UCHL1-Related Cancers Is Associated with Genomic Instability and Sensitivity to DNA-Damaging Treatment
Cancers 2023cited by 3position: middledoi
DNA-methylation and genomic copy number in primary tumors and corresponding lymph node metastases in prostate cancer from patients with low and high Gleason score
Clinical and Translational Radiation Oncology 2023cited by 2position: middledoi
Simultaneous metabolite MALDI-MSI, whole exome and transcriptome analysis from formalin-fixed paraffin-embedded tissue sections
Laboratory Investigation 2022cited by 17position: middledoi
Biopsy-derived oral keratinocytes – A model to potentially test for oral mucosa radiation sensitivity
Clinical and Translational Radiation Oncology 2022cited by 9position: middledoi
DeepClassPathway: Molecular pathway aware classification using explainable deep learning
European Journal of Cancer 2022cited by 9position: middledoi
Integration of p16/HPV DNA Status with a 24-miRNA-Defined Molecular Phenotype Improves Clinically Relevant Stratification of Head and Neck Cancer Patients
Cancers 2022cited by 5position: middledoi
Analysis of clonogenic growth in vitro
Nature Protocols 2021cited by 133position: middledoi
Early senescence and production of senescence-associated cytokines are major determinants of radioresistance in head-and-neck squamous cell carcinoma
Cell Death and Disease 2021cited by 72position: middledoi
Inhibition of HSP90 as a Strategy to Radiosensitize Glioblastoma: Targeting the DNA Damage Response and Beyond
Frontiers in Oncology 2021cited by 30position: middledoi
Tumor <scp>DNA‐methylome</scp> derived epigenetic fingerprint identifies <scp>HPV</scp>‐negative head and neck patients at risk for locoregional recurrence after postoperative radiochemotherapy
International Journal of Cancer 2021cited by 4position: middledoi
Improved risk stratification in younger<i>IDH</i>wild-type glioblastoma patients by combining a 4-miRNA signature with<i>MGMT</i>promoter methylation status
Neuro-Oncology Advances 2020cited by 4position: middledoi
Prospektive Validierung einer prognostischen 4-miRNA-Signatur bei Glioblastom-Patienten
Forum 2020cited by 0position: middledoi
Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis
Science Advances 2019cited by 221position: middledoi
A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection
Clinical Cancer Research 2018cited by 69position: middledoi
Ionizing radiation biomarkers in epidemiological studies – An update
Mutation Research/Reviews in Mutation Research 2017cited by 151position: middledoi
A 4-miRNA signature predicts the therapeutic outcome of glioblastoma
Oncotarget 2016cited by 45position: middledoi
OC-0441: Genomic amplification of FancA in HNSCC: mechanisms of radioresistance and clinical relevance
Radiotherapy and Oncology 2016cited by 0position: middledoi
Novel Approach of MALDI Drug Imaging, Immunohistochemistry, and Digital Image Analysis for Drug Distribution Studies in Tissues
Analytical Chemistry 2014cited by 44position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Claus Belka · Cancer Research Center12 papers (2016–2024)Kristian Unger · German Cancer Research Center9 papers (2016–2024)Julia Heß · Helmholtz Zentrum München8 papers (2020–2024)Kirsten Lauber · German Cancer Research Center8 papers (2016–2022)Maximilian Niyazi · Cancer Research Center5 papers (2016–2023)Axel Walch · University of Alaska Anchorage4 papers (2014–2022)Ute Ganswindt · Innsbruck Medical University3 papers (2016–2023)Philipp Baumeister · Ludwig-Maximilians-Universität München3 papers (2022–2024)Frederick Klauschen · Institute of Clinical Cancer Research3 papers (2022–2023)K. Unger · German Cancer Research Center3 papers (2016–2025)Theresa Heider · LMU Klinikum3 papers (2020–2022)Michael Orth · LMU Klinikum3 papers (2016–2021)Benedikt Luka · Medizinische Hochschule Hannover2 papers (2021–2022)Jochen Herms · Schön Klinik Bad Aibling2 papers (2020–2020) · 2 papers (2014–2022)Viktoria Ruf · LMU Klinikum2 papers (2020–2020)Daniel F. Fleischmann · German Cancer Research Center2 papers (2020–2020) · 2 papers (2020–2021)Ulrike Pflugradt · Ludwig-Maximilians-Universität München2 papers (2022–2024)Peter Weber · Technical University of Munich2 papers (2022–2025)